Dr. Reddy’s Laboratories Ltd announced today that it has launched Paricalcitol Injection, USP, in 2 mcg, 5 mcg, 10 mcg, a therapeutic equivalent generic version of Zemplar (paricalcitol) Injection in the United States market approved by the U.S. Food & Drug 
Administration (USFDA).
The Zemplar brand and generic had U.S. sales of approximately $22.5 million MAT for the most recent twelve months ending in July 2016 according to IMS Health.
Dr. Reddy’s Paricalcitol Injection is available in 2 mcg, 5 mcg, and 10 mcg, and is the first ANDA product launched in the US market.
Zemplar is a registered trademark of ABBVIE Inc.
